glp-1 advantage book The Your GLP-1 Game Plan
Description
Sato, Y
Key post hoc analysis of the landmark Steno-2 trial showing that intensified, multifactorial treatment slows progression of diabetic nephropathy and renal function loss in microalbuminuric patients with T2DM
Prescription GLP-1 medications undergo rigorous clinical trials, require medical supervision, and achieve average weight loss of 15-25% in clinical trials
Wang P, Alvarez-Perez JC, Felsenfeld DP, et al
Alloxan is a substance used as diabetogenic agent to induce T1DM in experimental animals and promotes selective inhibition of glucose-induced insulin secretion by inhibiting hexokinase 22
